# Wayne Eskridge

熱門 Podcast 單集
已更新:

S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future

Send us Fan Mail Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.00:00:00 …

S5 - E7.2 - Identifying the target MASH patients for Rezdiffra

Send us Fan Mail This conversation focuses on two issues: (i) identifying the right target MASH patients for Rezdiffra, and (ii) the extensive Madrigal patient support program for Rezdiffra.It starts with Roger Green asking the group how the current set of target patients is defined. Jeff McIntyre …

S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug

Send us Fan Mail This conversation focuses on advocates' reactions throughout the day on Thursday, March 14, the day Rezdiffra became the first MASH drug approved in the U.S. Specifically, panelists discuss their thoughts and feelings as they reflected on Rezdiffra’s approval in the context of thei…

S5 - E7.3 - Patient advocacy and the Rezdiffra label

Send us Fan Mail This conversation focuses on the steps that patient advocates took to educate the FDA on what patients wanted in a MASH drug label, in this case for Rezdiffra. It starts with Jeff McIntyre reflecting on apparent changes in how the FDA thinks about labeling since the initial obetich…

S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval

Send us Fan Mail So far, this conversation has focused on Rezdiffra approval and its many forms of impact on MASLD patient advocates. This conversation considers their recommendation for others. The conversation starts with Roger Green's final question. He asks each panelist to identify a stakehold…

S5 - E22.6 - FROM THE VAULT: Patient Advocates Reflect On How The "System" Views MASH

Send us Fan Mail In this week's episode, Jeff Lazarus discusses the idea that the MASH community, including patient advocates, live in a "bit of a bubble," where the clinicians with whom they interact are part of the MASH community. Last year's ICER Public Comments session exposed them to an FDA Ad…

Episode 33: The Silent Threat of Liver Disease and How to Combat It with Wayne Eskridge

In this episode of The DNA of Things, host Dr. Jeremy Koenig welcomes Wayne Eskridge, founder and CEO of the Fatty Liver Foundation, to discuss his transformative journey from engineering innovator to passionate health advocate. After being misdiagnosed with non-alcoholic steatohepatitis (NASH), Wa…

From research to advocacy: A new fellowship honors Stephen Harrison’s vision in MASH research

The sudden passing of Dr. Stephen Harrison in 2024 marked the loss of a visionary liver disease researcher and compassionate advocate. His legacy lives on through a new fellowship program that aims to educate and empower patient advocates in MASH. Led by the Fatty Liver Foundation with support from…

S6.14 - Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program

Send us Fan Mail 00:00:00 - Surf's Up: Season 6 Episode 14Louise Campbell and Roger Green interview key players in the inaugural Dr. Stephen A. Harrison Patient Advocacy Fellowship program, including Wayne Eskridge of the Fatty Liver Foundation (FLF), which initiated the program, Program Coordinato…

S6.14.2 - Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program

Send us Fan Mail In June, the Fatty Liver Foundation officially launched the Stephen A. Harrison Patient Advocacy program and announced its first class of 20 Fellows. In today's conversation, the program's organizers, Fatty Liver Foundation President Wayne Eskridge and Program Co-ordinator Elena Sa…